In myeloproliferative neoplasms (MPNs), a recent study showed that constitutive JAK2 activation induces chromatin-level alterations, particularly in enhancer utilization which promotes NFkB signaling, resulting in resistance to JAK inhibition [39]. The gene discussed is JAK2; the disease is myeloproliferative disorder.